Triple-Negative Breast Cancer Market to Showcase Growth at 4.7% CAGR Through 2034 | DelveInsight
The TNBC market is projected to expand, driven by rising disease prevalence, advances in targeted treatment options, and the introduction of new therapies, including DATROWAY [(Datopotamab Deruxtecan), AstraZeneca and Daiichi Sankyo], IMFINZI [(Durvalumab), AstraZeneca], PADCEV [(Enfortumab vedotin), Astellas Pharma and Pfizer], Tilarginine
